Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Hearing Loss 2Tinnitus 1Ototoxicity 1Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Deafness 1

Interventions

sodium thiosulfate 3ebselen 2Ankle Brachial Index 2Acetylcysteine 2Tomography, X-Ray Computed 1Sodium Chloride 1Saline Solution 1Ringer's Lactate 1Radiotherapy 1Radiosurgery 1Platinum 1Ofloxacin 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Hyaluronic Acid 1Hearing Tests 1Hearing 1Genetic Association Studies 1Ear Protective Devices 1Drug Therapy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Audiometry, Pure-Tone 1Atorvastatin 1Acoustic Impedance Tests 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hearing Loss × ebselen × Clear all
NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

NCT01452607 2016-06-29

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

Sound Pharmaceuticals, Incorporated

Phase 1 Completed
32 enrolled

Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡